Form 4: AnaptysBio Director Rita Jain Acquires Stock Options and Restricted Stock Units

Director Rita Jain acquired stock options and restricted stock units in AnaptysBio, Inc. on January 7, 2025.

Summary

• On January 7, 2025, Rita Jain, a director of AnaptysBio, Inc., acquired 16,510 stock options with an exercise price of $14.83.
• These options vest monthly starting February 7, 2025, and expire on January 6, 2035.
• Jain also acquired 6,030 restricted stock units (RSUs) which represent the right to receive common stock.
• These RSUs vest 100% on the date of the Issuer's 2026 annual meeting of shareholders, contingent on continued service.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of stock options and RSUs could be seen as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options and RSUs by a director may positively influence shareholder sentiment.

Key Dates